Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients

Diabetes

Volumn 47, Issue 1, 1998, Pages 130-133

  Cominacini, Luciano ^a,d   Garbin, Ulisse ^a   Pasini, Anna Fratta ^a   Campagnola, Mario ^a   Davoli, Anna ^a   Foot, Elizabeth ^c   Sighieri, Giuseppe ^b   Sironi, Anna M ^b   Lo Cascio, Vincenzo ^a   Ferrannini, Ele ^b  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c GLAXOSMITHKLINE   (United Kingdom)

^d UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HIGH DENSITY LIPOPROTEIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TROGLITAZONE; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPID PEROXIDATION; LIPOPROTEIN METABOLISM; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; RANDOMIZED CONTROLLED TRIAL;

EID: 17744404395     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.47.1.130     Document Type: Article

References (31)

1. Saltiel AR, Olefsky JM: Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45:1661-1669, 1996
2. Kumar S, Boulton AJM, Beck-Nielsen H, Berthezene F, Muggeo M, Persson B, Spinas GA, Donoghue S, Lettis S, Stewart-Long P, for the Troglitazone Study Group: Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 39:701-709, 1996
3. Yoshioka T, Fujita T, Kanai T: Studies on hindered phenols and analogues. I. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation. J Med Chem 32:421-427, 1989
4. Cominacini L, Garbin U, Pastorino AM, Campagnola M, Fratta Pasini A, Davoli A, Rigoni A, Lo Cascio V: Effects of troglitazone on in vitro oxidation of LDL and HDL induced by copper ions and endothelial cells. Diabetologia 40:165-172, 1997
5. Cominacini L, Young MMR, Capriati A, Garbin U, Fratta Pasini A, Campagnola M, Davoli A, Rigoni A, Contessi GB, Lo Cascio V: Troglitazone increases the resistance of LDL to oxidation in healthy volunteers. Diabetologia 40:1211-1218, 1997
6. Steinberg D, Parthasarathy SS, Carew TE, Khoo JC, Witztum JL: Beyond cholesterol: modification of low-density lipoprotein that increases its atherogenicity. N Engl J Med 320:915-924, 1989
7. Cominacini L, Garbin U, Pastorino AM, Fratta Pasini A, Campagnola M, De Santis A, Davoli A, Lo Cascio V: Increased susceptibility of LDL to in vitro oxidation in patients with insulin-dependent and non-insulin-dependent diabetes mellitus. Diabetes Res 26:173-184, 1994
8. Hunt J, Wolff SP: Oxidative glycation and free radical production: a causal mechanism of diabetic complications. Free Rod Res Commun 12-13:115-123, 1991
9. Cominacini L, Fratta Pasini A, Garbin U, Campagnola M, Davoli A, Rigoni A, Zenti MG, Pastorino AM, Lo Cascio V: E-selectin plasma concentration is influenced by glycaemic control in NIDDM patients: possible role of oxidative stress. Diabetologia 40:584-589, 1997
10. Nourooz-Zadeh J, Tajaddini-Sarmadi J, McCarthy S, Betteridge JD, Wolff SP: Elevated levels of authentic plasma hydroperoxides in NIDDM. Diabetes 44:1054-1058, 1995
11. Khan BV, Parthasarathy SS, Alexander RW, Medford RM: Modified low density lipoprotein and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells. J Clin Invest 95:1262-1270, 1995
12. Cominacini L, Garbin U, Fratta Pasini A, Davoli A, Campagnola M, Contessi GB, Pastorino AM, Lo Cascio V: Antioxidants inhibit the expression of inter- cellular cell adhesion molecule-1 and vascular cell adhesion molecule-1 induced by oxidized LDL on human umbilical vein endothelial cells. Free Rod Biol Med 22:117-127, 1997
13. Gearing AJH, Newman W: Circulating adhesion molecules in disease. Immunol Today 14:506-512, 1997
14. Lampeter ER, Kishimoto TK, Rothlein R, Mainolfi EA, Bertrams J, Kolb H, Martin S: Elevated levels of circulating adhesion molecules in IDDM patients and in subjects at risk for IDDM. Diabetes 41:1668-1671, 1992
15. Steiner M, Reinhardt KM, Krammer B, Ernst B, Blann AD: Increased levels of soluble adhesion molecules in type 2 (non-insulin dependent) diabetes mellitus are independent of glycaemic control. Thromb Haemost 72:979-984, 1994
16. Cominacini L, Fratta Pasini A, Garbin U, Davoli A, De Santis A, Campagnola M, Rigoni A, Zenti MG, Moghetti P, Lo Cascio V: Elevated levels of soluble E- selectin in patients with IDDM and NIDDM: relation to metabolic control. Diabetologia 38:1122-1124, 1995
17. Havel RJ, Eder MA, Bragdon JM: The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34:1345-1353, 1955
18. Cominacini L, Garbin U, Davoli A, Micciolo R, Bosello O, Gaviraghi G, Scuro LA, Pastorino AM: A simple test for predisposition to LDL oxidation based on the fluorescence development during copper-catalyzed oxidative modification. J Lipid Res 32:349-358, 1991
19. Huggett ASG, Nixon DA: Use of glucose oxidase, peroxidase and O-dianisidine in determination of blood and urinary glucose. Lancet ii:368-370, 1957
20. lc. Chim Biochem 18:32-36, 1985
21. Sasahara M, Raines EW, Chait A, Carew TE, Steinberg D, Wahl PJ, Ross R: Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. Is the extent of atherosclerosis related to resistance of LDL to oxidation? J Clin Incest 94:155-164, 1994
22. Regnstrom JN, Nilsson J, Tornavall P, Landou C, Hamsten A: Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man. Lancet 339:1183-1186, 1992
23. Cominacini L, Garbin U, Pastorino AM, Davoli A, Campagnola M, De Santis A, Pasini C, Faccini GB, Trevisan MT, Bertozzo L, Pasini F, Lo Cascio V: Predisposition to LDL oxidation in patients with and without angiographically established coronary artery disease. Atherosclerosis 99:63-70, 1993
24. Mao SJ, Yates MT, Rechtin AE, Jackson RI, Van Sickle WA: Antioxidant activity of probucol and its analogues in hypercholesterolemic Watanabe rabbits. J Med Chem 34:298-302, 1991
25. Dieber-Rotheneder M, Puhl H, Waeg G, Striegl G, Esterbauer H: Effect of oral supplementation with alpha-tocopherol on the vitamin E content of human low density lipoproteins and resistance to oxidation. J Lipid Res 32:1325-1332, 1991
26. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA. Willet WC: Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 328:1450-1456, 1993
27. Stampfer MJ, Hennekens CH, Manson JE, Colditz, GA, Rosner B, Willet WC: Vitamin E consumption and the risk of coronary heart disease in women. N Engl J Med 328:1444-1449, 1993
28. Niki E: Antioxidants in relation to lipid peroxidation. Chem Phys Lipids 44:227-253, 1987
29. Esterbauer H, Rotheneder M, Striegl G, Waeg G., Ashy A, Sattler W, Jurgens G: Vitamin E and other lipophilic antioxidants protect LDL against oxidation. Fat Sci Technol 91:316-324, 1989
30. Joris I, Zand T, Nunnari JJ, Krolikowsky FJ, Majno G: Studies on the pathogenesis of atherosclerosis I. Adhesion and migration of mononuclear cells in the aorta of hypercholesterolemic rats. Am J Path 113:341-358, 1983
31. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331:1188-1193, 1994